Professor Abeer M. Al-Ghananeem, Ph.D.

Curriculum Vitae

Associate Dean, Research and Graduate Program Sullivan University College of Pharmacy 2100 Gardiner Lane Louisville, KY 40205 USA

Phone: (502) 413-8957 Mobile: (859) 420-8165

E-mail: aalghananeem@sullivan.edu

PROFESSIONAL HIGHLIGHTS:

Academic & Research Experience:

- Over \$2.5M in grants/contracts as Principal Invigorator and Co-PI
- Over 70 scientific publications/abstracts and patents or patents families pending.
- Citation Report (Google Scholar): h-index: 11; i10-index: 14; Sum of Times Cited: 380
- National and international news coverage on a medicated cavity fighting gum project funded by the Department of Defense Research Foundation
- Educational Research
- Advanced Drug Delivery and Pharmaceutics PharmD Courses design/execution/coordinating
- The Flipped Classroom: Course design/execution to improve student engagement and learning
- Pharmaceutical R&D and product development
- Member of multi States and Nationwide research grants review panels

Management & Leadership Experience:

- Honored as a certified Academic Leadership Fellow (ALFP) of the American Association of Colleges of Pharmacy (AACP).
- Associate Dean for Research and Graduate program, including oversight over:
 - o Strategic planning and monitoring/developing faculty scholarly initiatives
 - Executive Committee member and strategic planning member for the College of Pharmacy accreditation by the USA Accreditation Council for Pharmacy Education (ACPE)
 - Design and draft Graduate Program Prospectus and scholarly documents for The USA Southern Association of Colleges and Schools Commission on Colleges (SACSCOC)
 - o Embrace suitable environment for Student, staff, and faculty research initiatives
 - o Chair University wide IRB
 - o Chair Research Committee and Research Task Force
 - o Voting member University wide Academic Council
 - o Member at Faculty/Academic Leaders recruitments and search committees
 - o Actively engaged with Assistant Provost for International Affairs
- Establishment of the Office of Research Newsletter, with the mission to spotlight faculty and students scholarly accomplishments and to develop a community of innovative faculty
- Consult with pharma and biotechnology companies on drug delivery/product development
- Write U.S. and foreign patent applications and respond to office actions
- Leadership of R&D and FDA registration regulations of ANDA and NDA applications

- o Vice President for Scientific Affairs at a successful startup USA company
- Lead scientist for the first Kentucky state US FDA ANDA approved drug; intravenous dantrolene sodium (Revonto®)
- Led Chemistry, Manufacturing, and Control (CMC) presentations for US FDA NDA meetings

EDUCATION:

1999 Ph.D., Pharmaceutical Sciences (Pharmaceutics/Drug Delivery)

College of Pharmacy, University of Kentucky, Lexington, KY United States of America

B.Sc. Pharmacy, College of Pharmacy, Jordan University, Amman, Jordan, with Distinction

LICENSURE & TRAINING:

American Association of Colleges of Pharmacy Academic Leadership Fellow Actively participated and graduated the following leadership focus sessions:

- Leadership and Self: Discovery and Teamwork
- Leadership Potpourri: Constructing Skills, Historical Perspectives and Higher Education
- Selling in Leadership and Current Topics in Leadership and Higher Education
- Refining Self and Current Topics in Leadership

2003-2004 University of Kentucky, Lexington, KY - Post Doctorate Fellow, Industrial Pharmacy & Drug Delivery

2002-2003 University of Kentucky, Lexington, KY - Post Doctorate Fellow, Pharmaceutical Technology & Drug Delivery

1993-present Registered Pharmacist, Jordan

ADMINISTRATIVE POSITIONS:

2012-Present Associate Dean, Research and Graduate Programs Sullivan University, College of Pharmacy

Louisville, KY-USA

2008-2012 Vice President, Scientific Affairs

US WorldMeds, LLC Louisville, KY-USA

2005-2011 Graduate School Ph.D. Advisory Committees

University of Kentucky, College of Pharmacy

University of Kentucky, College of Arts & Sciences

Lexington, KY-USA

P	OSITIONS	& AC	ADEMIC	APPOINT	MENTS.
•					

2015-Present	Visiting Professor Al-Zaytoonah University of Jordan, College of Pharmacy, Amman, Jordan
2013-Present	Professor Sullivan University, College of Pharmacy, Department of Pharmaceutical Sciences Louisville, KY-USA
2012-2013	Associate Professor Sullivan University, College of Pharmacy, Department of Pharmaceutical Sciences Louisville, KY-USA
2008-2012	Associate Professor, PT Sullivan University, College of Pharmacy, Department of Pharmaceutical Sciences Louisville, KY-USA
2011-2012	Visiting Professor Jordan University, College of Pharmacy Amman, Jordan
2010-2011	Associate Professor, PT University of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences, Division of Drug Development and Delivery Lexington, KY-USA
2005-2009	Assistant Professor University of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences, Division of Drug Development and Delivery Lexington, KY-USA
2003-2004	Research Associate, Postdoctoral Fellow University of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences Lexington, KY-USA
2002-2003	Postdoctoral Scholar Fellow University of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences Lexington, KY-USA
2001-2002	Pharmaceutical Internship Eckerd Pharmaceutical Company Irving, TX-USA
2000-2001	Assistant Professor University of Jordan, College of Pharmacy, Department of Pharmaceutical Sciences Amman, Jordan
1996-1999	Teaching Assistant, Graduate Student University of Kentucky, College of Pharmacy, Department of Pharmaceutical Sciences Lexington KY-USA

1993-1996 Lecturer, Teaching Assistant

University of Jordan, College of Pharmacy, Department of Pharmaceutical Sciences

Amman, Jordan

SELECTED PROFFESIONAL SERVICE:

College level	
2012-Present	Member, Sullivan University College of Pharmacy Executive Committee
2012-Present	Member, Sullivan University College of Pharmacy Management Team
2012-Present	Chair, Sullivan University College of Pharmacy Research Committee
2013-2014	Member, Sullivan University College of Pharmacy Curriculum Committee
2013-2014	Chair, Sullivan University College of Pharmacy Graduate Program Steering Committee
2014-Present	Member, Sullivan University College of Pharmacy Continuous Education Committee
2009-2010	Member, University of Kentucky College of Pharmacy Ethics and Professional Committee

University Level

2014-Present	Member, Sullivan University Academic Council
	Chair, Sullivan University IRB Committee
2013	Member, Sullivan University College of Pharmacy Dean Search Committee
2007-2008	Member, University of Kentucky Women Faculty Forum

2002-present Member, AAPS Inhalation and Nasal Technology Focus Group

National Level 2014-Present

I valional Leve	<u>1</u>
2014-Present	Member, American Association of Colleges of Pharmacy (AACP) Leadership Development
	Special Interest Group (SIG)
2013-2015	Reviewer, American Association of Colleges of Pharmacy (AACP) Express Scripts
	Scholarship Program
2013-Present	Member, AACP Curriculum Committee of the Graduate Education Special Interest Group
2013-Present	Chair, AACP Soft Skills in Graduate Education Sub-Committee
2013-Present	Member, AACP Teachers of Pharmaceutics Section (TOPS) Annual Meeting Program
	Committee
2013-Present	Member, American Association of Pharmaceutical Scientists (AAPS) Targeted Drug
	Delivery & Prodrug Focus Group Committee
2012-Present	Member, Kentucky Nanotechnology Symposium Steering Committee - University of
	Louisville, University of Kentucky, Sullivan University and Western Kentucky University.
2009-Present	Member, Ohio Valley Affiliates for Life Sciences (OVALS)

TEACHING EXPERIENCE:

PBS 626/627	Advanced Drug Delivery (2 credit hours): Coordinator and teaching full course to
	PharmD PY2 students
PBS 520	Biopharmaceutics and Pharmacokinetics (4 credit hours): Coordinator and teaching
	to PharmD PY1students
PHR 6003	Biopharmaceutics and Pharmacokinetics 1 (2 credit hours): Coordinator and
	teaching full course to PharmD PY2 students
PHR 5404	Pharmaceutical Biotechnology (1 credit hour): Teaching topics in Production,
	Processing, and Formulation of biotech products to PharmD PY2 students
PBS 518	Pharmaceutics II with Laboratory (4 credit hours): Teaching topics in solid,
	semisolid, and liquid dosage forms with laboratory to PharmD PY2 students
PHR 760	Introduction to Pharmaceutical Sciences (2 credit hours, elective): Teaching topics
	in drug development Good Manufacturing Practice (cGMP) per FDA guidelines to
	Ph.D. students

Further topics taught and/or coordinated across the academic experience to PharmD and Ph.D. students:

Pharmaceutical Technology
Special Topics in Drug Delivery
Clinical Pharmacokinetics I & II
Pharmaceutics I & II
Nanotechnology and Pharmaceutical Applications
Drug Development Policies & Guidelines
Dosage Form Design
Chromatography Application & Instrumental Analysis
Pharmacology and Medicinal Chemistry II, III, and IV
Wilderness Medicine

Ph.D. DISSERTATION COMMITTEE ACTIVITY:

A graduate faculty in the following University of Kentucky students' Ph.D. dissertation advisory committees

Harpreet Kaur Dhooper Ujjwal Chakraborty Joshua Eldridge Sujit Pawar

CONSULTANCIES:

Adams Respiratory Therapeutics Inc, USA
Ceptaris Therapeutics Inc, USA
Louisiana Board of Regents, USA
Teva Pharmaceutical Industries Ltd, USA
USWorldMeds LLC, USA
Union Springs, LLC, USA
Yaupon Therapeutics Inc, USA

HONORS AND AWARDS:

2008 Nanotechnology Symposium Outstanding Research Paper Award
2007 Pfizer Company Career Development Award
2006 American Cancer Society IRG Award
2006 Kentucky Science and Technology Corp. (KSTC) STTR/SIBR workshop award
1999 P&G Drug Delivery Award
1998 Rho Chi American Pharmaceutical Honor Society

AWARDED RESEARCH GRANTS:

- 1. Union Springs Industrial Grant: *Assessment and development of natural supplement based formulations for ADHD*, \$10,000 (6/2014-12/2014). Role: PI
- 2. US WorldMeds Industrial Grant: *Development of Stable Apomorphine Solutions and Oral Tablets Formulations*, \$136,000 (11/2012-11/2014). Role: PI
- 3. US Research Foundation: Formulation development of intravenous nanoemulsion and lipid-drug complex products, \$40,000 (10/2011-09/2012). Role: PI

- 4. KSTC R&D Grant, USWM, Formulation development of intravenous and oral dosage forms, \$338,572 (10/2007 09/2011). Role: PI
- 5. Swedish Match North America Inc. *Development of a microencapsulated system for food flavors*, \$275,796 (08/2005 09/2009). Role: PI since 08/2008
- 6. US Army Research Office, *Development of a sustained Antiplaque, antimicrobial delivery system for KSL*, \$400,390 (01/2004 09/2009). Role: PI since 08/2008
- 7. KSTC R&D Voucher: Product development and formulation, \$975,088 (05/2002-09/2010). Role: CO-I
- 8. Pfizer Company Career Development Award, \$10,000 (09/2007- 08/2008). Role: PI
- 9. American Cancer Society IRG: *Hyaluronan Microspheres and Nanoparticles as Chemotherapeutic Delivery Device in Cancer Therapy*, \$20,000 (01/2007 05/2008). Role: PI
- 10. NIH/NCI PO1 CA104457 Subcontract from University of Vanderbilt: *Pharmacokinetics of Novel Radiation Sensitizers*, \$31,330. Role: CO- I
- 11. NIH/STTR: Norketamine for Treatment of Pain, \$259,841. Role: CO-I
- 12. NIH RO1 GM076063 Subcontract from University of California: Formulation development for acid labile novel compound TRAM-34, \$8,881 (09/2007 05/2008). Role: PI
- 13. Airmid Company Industrial Contract: Formulation development for water insoluble novel compound PAP-1, \$12,371 (09/2007 02/2008). Role: PI

SELECTED SCIENTIFIC PROFESSIONAL PRESENTATIONS:

- 2015 Keynote Speaker: Nanotechnology Delivery Systems for Drug Targeting to the Brain through Intranasal Route. 1st International Conference of the Jordanian Faculties of Pharmacy "JFP", Amman, Jordan.
- 2015 Keynote Speaker: Transmucosal Drug Delivery as a Promising Avenue for Breakthrough Cancer Therapy. 5th Al-Zaytoonah University of Jordan International Pharmaceutical Conference (ZTIPC 2015), Amman, Jordan.
- 2015 Invited Speaker: Drug Development and Clinical Trials Challenges for Natural Products-Based Drug Candidates. 1st International Conference on Natural Products and Drug Discovery. Amman, Jordan.
- Invited Speaker: Eye on the Future: Transmucosal Drug Delivery as a Promising Avenue for Breakthrough Cancer Therapy. 1st International Controlled Release Society Congress. Aegli Zappiou, Greece.
- Invited Speaker: SUCOP residents Teaching Certificate Session: Intellectual Property, Scholarship of Teaching and Learning (SoTL), and Grant Writing. Louisville, Kentucky
- Speaker and Moderator: SU Graduate Students Retreat Session: IRB guidelines and application submission requirements. Louisville, KY, USA.
- 2014 Speaker: Evolving Trends in Pharmacy Education. DUPHAT International Pharmaceuticals and Technologies Conference and Exhibition, Dubai, UAE
- 2013 Invited Judge and Moderator: 2nd Arab Innovation Network Annual Conference. Dead Sea, Jordan.
- 2013 Speaker: Transmucosal Drug Delivery for Breakthrough Cancer Therapy, DUPHAT International Pharmaceuticals and Technologies Conference and Exhibition, Dubai, UAE
- Invited Guest Speaker: Trends and Innovations in Pharmacy Education. Jordan University, College of Pharmacy. Amman, Jordan.
- Invited Guest Speaker: Trends and Innovations in Pharmacy Education. Al-Zaytoonah University, College of Pharmacy. Amman, Jordan.

2013 Invited Guest Speaker: Graduate Education in USA. The 3rd Students Pharmaceutical conference by Jordan Board of Pharmacy. Amman, Jordan. 2013 Speaker: Hyaluronic Acid Nanoparticles for Sustained Paclitaxel Delivery after Intra-Tumor Injection. 1st Annual Kentucky Nanotechnology Symposium. University of Louisville. Louisville, Kentucky, USA. 2012 Invited Speaker: The New Trends in Pharmacy Education and Practice. The 14th Annual Congress of the Scientific Association of Colleges of Pharmacy in the Arab World & The 2nd International Conference of the College of Pharmacy and Health Sciences, in Ajman UAE 2011 Invited Speaker: Challenges in Parenteral Dosage Form Preparations of Slightly Water-Soluble Drugs: Dantrolene Sodium a Successful Example of Academic-Industrial Collaboration. The 3rd International Conference on Drug Discovery and Therapy, Dubai. 2010 Speaker, Symposium in Drug Discovery and Development. Lexington, KY, USA 2010 Invited Speaker: Pharmaceutical Development and Advances in Analytical Chemistry. The 5th National Analytical Chemistry Congress in Erzurum, Turkey Speaker: Nanotechnology and Therapeutics, International Conference on RNA, Cleveland, 2010 OH, USA Invited Speaker: Engineered Nanoparticles for Intratumor Cancer Therapy. International 2009 Congress on Tissue Engineering, Alexandria, Egypt Invited Speaker: Nanoparticulate Delivery Systems for Drug Targeting to the Brain through 2009 Intranasal Drug Delivery. The Sullivan University Nanotechnology Symposium, Louisville, KY, USA 2008 Invited Speaker: Nanotechnology in Breast Cancer Therapy. The Sullivan University Nanotechnology Symposium, Louisville, KY, USA Organizer and Moderator of Sunrise Session: Assessment of Nasal Drug Delivery in 2007 Humans Using Radionuclide Imaging Techniques. American Association of Pharmaceutical Scientists Annual meeting in San Diego, CA, USA Speaker: Paclitaxel-Loaded Cross-Linked Hyaluronan Nanoparticles for Breast Cancer 2007 Therapy. 16th International Symposium on Microencapsulation, Lexington, KY, USA.

EDITORIAL ACTIVITIES:

2013- on	Editorial Board, Member, Clinical & Experimental Pharmacology
2007-on	Editorial Board, Member, Jordan Journal of Pharmaceutical Sciences
2009- on	Editorial Board, Member, Journal of Advanced Research
2011- on	Editorial Board, Member, International Journal of Life Sciences and Medical reviews
1999-on	Reviewer, Journal of Pharmaceutical Sciences
1999-on	Reviewer, AAPS PharmSci Tech Journal
2005-on	Reviewer, European Journal of Pharmaceutics and Biopharmaceutics
2007-on	Reviewer, Letters in Drug Design and Discovery
2008-on	Reviewer, Nature Protocols
2009-on	Reviewer, Journal of Drug Targeting
2009-on	Reviewer, Journal of Microencapsulation

VISITING SCHOLARS TO PROFESSOR AL-GHANANEEM RESEARCH GROUP:

Dr. Mohammad Harb PhD., Assistant Professor, Sharjah University, 2011 Dr. Bashar El Khaldi PhD., Assistant Professor, University of Jordan, 2010

- Dr. Ahmed Hassan PhD., Professor, University of Damascus, 2010
- Mr. Mohammed Atiqzaman MS., Scientist, University of Bangladesh, 2009-2010
- Dr. Maggie Abbassi PhD., Assistant Professor, University of Cairo, 2008
- Dr. Hayder Saeed MD., PostDoctoral Scholar, University of Baghdad, 2007-2009

PROFESSIONAL AFFILIATIONS:

- Rho Chi American Pharmaceutical Honor Society (1998-present)
- American Association of Pharmaceutical Scientists (AAPS) (1998-present)
- American Association of Colleges of Pharmacy (AACP) (2003-present)
- Parenteral Drug Association (PDA) (2009-2010)
- Controlled Release Society (CRS) (2012-2015)
- American Chemical Society (ACS) (2008-2010)
- Jordan Association of Pharmacists (1993-present)
- Scientific Advisory Board, US WorldMeds, LLC (2005-2012)
- University of Kentucky Graduate Faculty (2005-2013)
- Susan Komen Breast Cancer Foundation (2005-2009)
- University of Sullivan College of Pharmacy, Nanosymposium International Advisory Board (2009-2011)
- Kentucky Nano Symposium Steering Committee (2012-present)

RECORDS OF INVENTIONS:

- 1. Co-solvent System for the Preparation of a Rapidly Reconstituted Freeze-dried Dantrolene Sodium Drug Product for Intravenous Injection. Ahmad Malkawi, Abeer Al-Ghananeem, Patrick DeLuca, and George A. Digenis. USPTO 20110160261 (2011)
- 2. Intranasal Delivery System for Dantrolene. Abeer M. Al-Ghananeem. PCT/US2010/032375 (2010)
- 3. Ketorolac Sublingual Spray for the Treatment of Pain. Abeer M. Al-Ghananeem. USPTO 20090246273A1 (2009)
- 4. Skin Patches and Sustained-Release Formulations Comprising Lofexidine for Transdermal and Oral Delivery. Abeer M. Al-Ghananeem. PCT/US09/048621 (2009)
- 5. Transmucosal drug delivery of Lofexidine. Abeer M. Al-Ghananeem. PCT/US09/38172 (2009)
- 6. Transdermal Delivery of Apomorphine Hydrochloride Using Microneedles. Abeer M. Al-Ghananeem, PCT/US09/54604 (2009)
- 7. Stabilized compositions of volatile alkylating agents and methods of using thereof. Crooks PA, Lessin SR, Pimley MA, Alonso R, Al-Ghananeem A. PCT international application WO/2006/099385 (2007), European Patent No. EP1858864 (2007), U.S. patent Application No. US2008/0194699 (2008)
- 8. Lofexidine enantiomers for use as a treatment for CNS disease and pathologies and its chiral synthesis. Digenis G, Crooks, PA, and Al-Ghananeem A. U.S. Patent No: US 2006-376710 20060314. Priority: US 2005-661525 20050314 (2008)
- 9. Scopolamine sublingual spray for the treatment of motion sickness. Crooks P, Al-Ghananeem A, and Malkawi A. U.S. Patent No.: US 2006-360690 20060224. Priority: US 2005-656359 20050225 (2006)
- 10. Sublingual spray for the treatment of pain. By Peter A. Crooks, Abeer Al-Ghananeem, and Ahmad H. Malkawi, PCT Int. Appl. No. WO 2006105205. Priority: US 2005-666060 (2006)
- 11. Intranasal codeine for the rapid suppression of cough and rapid relief of pain. Hussain A, Dittert L, and Al-Ghananeem A. PCT international application WO 99-US23788 19991014. Priority: US 98-104272 19981014 (2000)

PUBLISHED BOOKS:

Drug Targeting to the Lung: Chemical and Biological Consideration. Crooks PA and Al-Ghananeem AM. *Pharmaceutical Aerosol Technology; Drugs and the Pharmaceutical Sciences Series/134*, Second edition. Anthony Hickey, Marcel Dekker, NY 200X 0097142232646. ISBN: 0-8247-4253-2. Sept 2003.

Nanoparticles as Delivery System in Breast Cancer Therapy. Al-Ghananeem AM and Saeed H. *Advances in Nanotechnology and Applications*, Volume 1. Pathak YV and Tran HT, Center for Nanotechnology: Education, Research, and Applications, 1-4392-5489-3. Oct 2009.

PEER-REVIEWED PUBLICATIONS:

*Corresponding author

- 1. **Biotechnology in practice: call for incorporation of biosimilars into pharmacy education.** Malcom DR and <u>Al-Ghananeem AM*</u>. *Currents in Pharmacy Teaching and Learning*. 2014, doi: http://dx.doi.org/10.1016/j.cptl.2014.11.001
- 2. **Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.** Baltzley S, Mohammad A, Malkawi AH, <u>Al-Ghananeem AM*</u>. *AAPS PharmSciTech*. 2014, 15(4). doi: 10.1208/s12249-014-0189-5
- 3. Advances in brain targeting and drug delivery of anti-HIV therapeutic agents. Al-Ghananeem AM*, Michael Smith, Maria Coronel, Hieu Tran. Expert Opinion on Drug Delivery. 2013, 10(7), 973-985.
- 4. Sublingual and nasal transmucosal drug delivery for breakthrough pain: a frontier in cancer therapy. <u>Al-Ghananeem AM</u>*. *Journal of Bioequivalence and Bioavailability*. 2013, 5(3), *Editorial*. doi:10.4172/jbb.10000e29
- 5. Bioavailability of Δ⁹-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. <u>Al-Ghananeem AM</u>*, Malkawi AH, Crooks, PA. *Drug Dev Ind Pharm*.2011, 37(3), 329-334.
- 6. Formulation-based approach to support early drug discovery efforts: a case study with enteric microencapsulation dosage form development for a triarylmethane derivative TRAM-34; a novel potential immunosuppressant. Al-Ghananeem AM*, Abbassi M, Shrestha S, Raman G, Wulff H, Pereira L, Ansari A. *Drug Dev Ind Pharm.* 2010, 36(5), 563-569
- 7. Intranasal drug delivery of didanosine loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses. Al-Ghananeem AM*, Saeed H, Florence R, Yokel RA, Malkawi AH. *Journal of Drug Targeting*. 2010, 18(5), 381-388.
- 8. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Mansour HM, Sohn M, Al-Ghananeem AM, DeLuca PP. *International Journal of Molecular Sciences*. 2010, 11, 3298-3322.

- 9. Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate dependent patients. Al-Ghananeem AM*, Herman B, Abbassi M, Yu E, Miotto K, O'Brien; Ling; Montgomery A, Walsh R. *Am J Drug Alcohol Abuse*. 2009, 35(5), 311-315.
- 10. **Intratumoral Delivery of Paclitaxel in Solid Tumor from Biodegradable Hyaluronan Nanoparticle Formulations.** <u>Al-Ghananeem AM</u>*, Malkawi AH, Muammer YM, Balko JM, Black EP, Mourad W, Romond E. *AAPS PharmSciTech.* 2009, 10(2), 410-117.
- 11. **Pharmacokinetics of Lofexidine Hydrochloride in Healthy Volunteers**. <u>Al-Ghananeem AM</u>*. *J Pharm Sci.* 2009, 98(1), 319-326.
- 12. Nicotine exposure can be detected in cerebrospinal fluid of active and passive smokers. Malkawi, AH, Al-Ghananeem, AM, de Leon J, Crooks PA. *J Pharmaceut Biomed.* 2009, 49(1), 129-132.
- 13. Clinical Pharmacokinetics of Lofexidine, the α2-Adrenergic Receptor Agonist, in Opiate Addicts Plasma Using a Highly Sensitive Liquid Chromatography Tandem Mass Spectrometric Analysis. Yu E, Miotto K, Akerele E, O'Brien CP, Ling W, Kleber H, Fischman MW, Elkashef A, Herman BH, and Al-Ghananeem AM*. Am J Drug Alcohol Ab. 2008, 34, 611–616.
- 14. Gamma Scintigraphy for Testing Bioequivalence: A Case Study on Two Cromolyn Sodium Nasal Spray Preparations. Al-Ghananeem AM*, Sandefer EP, Doll WJ, Page RC, Chang Y, Digenis GA. *Int J Pharm.* 2008, 357(1-2), 70–76.
- 15. **Development of a GC-MS Assay for the Determination of Fentanyl Pharmacokinetics in Rabbit Plasma after Sublingual Spray Delivery.** Malkawi AH, <u>Al-Ghananeem AM</u>, and Crooks PA. *AAPS J.* 2008, (10)2, 261-267.
- 16. **An HPLC Method for the Simultaneous Determination of Neurotoxic Dipyridyl Isomers in Human Plasma.** Malkawi A, <u>Al-Ghananeem AM</u>, Naseem S, de Leon J and Crooks PA. *J Pharmaceut Biomed.* 2007, 45(1), 120-124.
- 17. Pharmacokinetic Study on Oral Z-(±)-2-(1-Benzylindole-3-yl-methylene)-azabicyclo-[2.2.2] octane-3-ol; a Novel Radio-sensitization Agent. Al-Ghananeem AM, Al-Bayati Z, Malkawi AH, Sonar VN, Freeman ML and Crooks PA. A Cancer Chemoth Pharma. 2007, 60(6), 915-919.
- 18. A Novel Chemical Delivery System Comprising an Ocular Sustained Release Formulation of a 3α, 17α, 21-trihydroxy-5β-pregnan-20-one-BIS-5-Flourouracil Codrug. Howard-Sparks M, Al-Ghananeem AM, Pearson A and Crooks PA. *Drug Dev Ind Pharm.* 2007, 33, 677-684.
- 19. Scopolamine Sublingual Spray: An Alternative Route of Delivery for the Treatment of Motion Sickness. Al-Ghananeem AM*; Malkawi AH and Crooks PA. *Drug Dev Ind Pharm.* 2007, 33, 577-582.
- 20. Phase I and Phase II Ocular Metabolic Activities and the Role of Metabolism in Ophthalmic Prodrug and Codrug Design and Delivery. Al-Ghananeem AM and Crooks PA. *Molecules*. 2007, 12, 373-388.

- 21. Opiate Receptor Binding Properties of Morphine-, Dihydromorphine-, and Codeine 6-*O*-sulfate Ester Congeners. Crooks PA, Kottayil S, <u>Al-Ghananeem AM</u>, Byrn S and Butterfield A. *Bioorg Med Chem Lett.* 2006, 16(16), 4291-4295.
- 22. Assessment of Nasal Drug Delivery in Humans Using Radionuclide Imaging Techniques. Al-Ghananeem AM and Crooks PA. *Pharmaceutical Formulation and Quality.* 2006, 8(4), 38-43.
- 23. **Synthesis and Stability of Two Indomethacin Prodrugs**. Chandrasekaran S, <u>Al-Ghananeem</u> AM, Riggs R and Crooks PA. *Bioorg Med Chem Lett.* 2006, 6(7), 1874-1879.
- 24. **Effect of pH on Sublingual Absorption of Oxycodone Hydrochloride**. <u>Al-Ghananeem AM</u>, Malkawi AH and Crooks PA. *J Pharm Sci Technol*. 2006, 7(1), E23.
- 25. Evaluation of $O^{3\alpha}$ -, O^{21} -di-(N^1 -methyloxycarbonyl-2,4-dioxo-5-fluoropyrimidinyl)17α-hydroxy-5β-pregnan-20-one as a Novel Potential Antiangiogenic Codrug. Howard-Sparks M, Al-Ghananeem AM, Pearson A and Crooks PA. *J Enzyme Inhib Med Chem.* 2005, 20(5), 417-428.
- 26. **Novel Antiglaucoma Prodrugs and Codrugs of Ethacrynic Acid.** Cynkowska G, Cynkowski T, <u>Al-Ghananeem AM</u>, Guo H, Ashton P and Crooks PA. *Bioorg Med Chem Lett.* 2005, 15(15), 3524-3527.
- 27. Targeted Brain Delivery of 17-β Estradiol via Nasally Administered Water Soluble Prodrugs. Al-Ghananeem AM, Traboulsi A, Dittert L and Hussain AA. *J Pharm Sci Technol.* 2002, 3(1), E5.

SELECTED ABSTRACTS/POSTERS:

- 1. Design, formulation and *in vitro* dissolution of core-coat oral tablets containing immediate release antiemetic and sustained release chemotherapeutic agent. Leah Johannes; Katie Trueblood; Katie Petrone; Catherine Pham; Anne Lei; Nu Nguyen; Sarah Baltzley; and Abeer Al-Ghananeem. (2015 AACP Annual Meeting, WA USA).
- **2. Development of Alternative Acetaminophen Formulations for Pediatrics.** Jason Knopp; Leon Le; Caitlyn Elmes; Sarah Baltzley; Abeer Al-Ghananeem. (2015 AACP Annual Meeting, WA USA).
- 3. Design and in-vitro release profiles for combined multilayer immediate release antiemetic and sustained release anticancer oral tablets. Petrone K, Baltzley S, <u>Al-Ghananeem AM</u>. (2014 ASHP Midyear Clinical Meeting, CA USA).
- **4. Design, synthesis and optimization of a novel amoxicillin-erdosteine codrug.** Camargo MA, Strano J, Smith M, Al-Ghananeem AM. (2014 ASHP Midyear Clinical Meeting, CA USA).
- **5.** A high-performance liquid chromatography (HPLC) stability indicating assay for Estradiol and related substances. Baltzley S and <u>Al-Ghananeem AM</u>. (2014 AACP Annual Meeting, Grapevine, TX USA).
- **6. Design, synthesis and kinetic study on a novel Amoxicillin-Erdosteine codrug.** Smith M, Baltzley S, Hoffman C, Al-Ghananeem AM. (2014 AACP Annual Meeting, Grapevine, TX USA).

- **7. Design and Evaluation of Multilayer and Core Sustained Release Tablets.** Curry D, Rosas S, Richardson M, Baltzley S, <u>Al-Ghananeem AM.</u> (2014 AACP Annual Meeting, Grapevine, TX USA).
- **8.** Olanzapine formulations for intranasal drug delivery. Baltzley S and <u>Al-Ghananeem AM.</u> (2013 AAPS Annual Meeting, San Antonio, TX, USA).
- **9.** Transdermal drug delivery of apomorphine using microneedles. <u>Al-Ghananeem AM</u>, Malkawi AH, and Saeed H. (2013 AACP Annual Meeting, Chicago, IL, USA).
- **10. Kinetics and mechanism of apomorphine hydrolysis.** Al-Ghananeem AM, Baltzley S, Zhao Y, Coronel L, Tran H. (2013 AACP Annual Meeting, Chicago, IL, USA).
- **11.** Novel experiential learning opportunity in pharmacy training: Molecular Biology research using cardiac stem cell model. Sumanasekera WK, Thy Dao H, Mehul J, Shultz K, Felix G, Abdi F, Al-Ghananeem AM, Coronel L, and Tran H. (2013 AACP Annual Meeting, Chicago, IL, USA).
- 12. Improvement of Academic Performances in a Pharmacy Didactic Course with the Initiation of Competency-Based Assessment. Zhao Z, Coronel L, Koomer A, Al-Ghananeem AM, Tran H. (2013 AACP Annual Meeting, Chicago, IL, USA).
- **13. Intranasal drug delivery of Olanzapine loaded chitosan nanoparticles.** Saeed H, Atiquzzaman M and <u>Al-Ghananeem AM</u>. (FIP Pharmaceutical Sciences 2010 World Congress in Association with the AAPS Annual Meeting and Exposition, New Orleans, LA, USA).
- **14.** In vivo assessment of paclitaxel-loaded hyaluronic acid nanoparticles in rats bearing **7,12-dimethylbenz**[A]anthracene (DMBA) induced tumor. Saeed H, Mourad W and Al-Ghananeem AM. (2009 AAPS Annual Meeting and Exposition, Los Angeles, CA, USA) Poster # R6259
- **15.** Intranasal drug delivery of didanosine loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by aids viruses. Saeed H, Florence R, Yokel R and Al-Ghananeem AM. (2009 AAPS Annual Meeting and Exposition, Los Angeles, CA, USA) Poster # R6358
- **16.** Incremental versus cumulative in vitro release testing: a case study with methyl salicylate release from a microencapsulated system. Saeed H, Sohn M, Ritchie C, DeLuca P and Al-Ghananeem AM. (2009 AAPS Annual Meeting and Exposition, Los Angeles, CA, USA) Poster # W5011
- 17. Paclitaxel-Loaded Nanoparticles Based on Hyaluronic Acid Chemically Cross-Linked with Glutaraldehyde for Intratumor Cancer Therapy. <u>Al-Ghananeem AM</u>. (2008 AAPS Annual Meeting and Exposition, Atlanta, GA, USA)
- 18. Enteric Coating Microencapsulation of TRAM-34, a Novel Potent and Selective Inhibitor of the Intermediate-conductance Ca²⁺-activated K⁺ Channel, KCa3.1: A Potential Immunosuppressant. Shrestha S, Wulff H, Raman G, Pereira LE, Muammer Y, Ansari AA, Villinger F, Al-Ghananeem AM. (2008 AAPS Annual Meeting and Exposition, Atlanta, GA, USA)

- 19. Preclinical Pharmacokinetic Evaluation of Z-(±)-2-(1-Benzenesulfonyl-1H-indol-3-ylmethylene)-1-azabicyclo[2.2.2]octan-3-one (BSAO); a Novel Radio-sensitization Agent. Al-Ghananeem AM, Malkawi AH, Al-Bayati ZF, Freeman ML, Crooks PA. (2008 AAPS Annual Meeting and Exposition, Atlanta, GA, USA)
- **20.** Gamma Scintigraphy for Testing Bioequivalence: A Case Study on Two Cromolyn Sodium Nasal Spray Preparations. Al-Ghananeem AM, Sandefer EP, Doll WJ, Page RC, Chang Y, Digenis GA. (2008 AAPS Annual Meeting and Exposition, Atlanta, GA, USA)
- **21.** Pharmacokinetics of Lofexidine Hydrochloride in Healthy Volunteers. <u>Al-Ghananeem AM.</u> (2008 AAPS Annual Meeting and Exposition, Atlanta, GA, USA).
- **22.** In vivo Assessment of Paclitaxel-Loaded Hyaluronic Acid Nanoparticles in Rats. Saeed H, Mourad M, Romond E and <u>Al-Ghananeem AM</u>. (*Markey Cancer Center Research Day, University of Kentucky*, Lexington, KY, USA)
- **23.** Does the Use of Warmed Water for Injection Accelerate the Reconstitution of the Sparingly Water Soluble Drug Dantrolene Sodium. Al-Ghananeem AM, Malkawi AH, Digenis GA, DeLuca P and Crooks PA. (2007 AAPS Annual Meeting and Exposition, San Diego, CA, USA)
- **24.** A Pharmacokinetic Study on Z-(±)-2-(1-Benzylindole-3-yl-methylene)azabicyclo-[2.2.2]-octane-3-ol; a Novel Radio-sensitization Agent. Al-Ghananeem AM, Al-Bayati Z, Malkawi A, Sonar VN, Freeman ML and Crooks PA. (2007 AAPS Annual Meeting and Exposition, San Diego, CA, USA)
- 25. Development and Validation of a Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS) Method for the Determination of the Novel Radiosensitization Agent; Z-(±)-2-(1-Benzylindole-3-yl-methylene)azabicyclo-[2.2.2]-octane-3-ol (BMABO). Al-Ghananeem AM, May J, Rogers B, Malkawi A, Thirupathi R, Sonar VN, and Crooks PA. (2007 AAPS Annual Meeting and Exposition, San Diego, CA, USA)
- **26. Kinetic Studies on Dantrolene Sodium.** <u>Al-Ghananeem AM</u>*, Malkawi AH, Digenis GA, DeLuca P and Crooks PA. (2007 AAPS Annual Meeting and Exposition, San Diego, CA, USA)
- 27. A Pharmacokinetic Study on Z-(±)-2-(1-Benzylindole-3-yl-methylene)azabicyclo-[2.2.2]-octane-3-ol; a Novel Radio-sensitization Agent. Al-Ghananeem AM*, Al-Bayati Z, Malkawi AH, Sonar VN, Rogers B, Freeman ML and Crooks PA. Forefront of Basic and Translational Cancer Research 7th American Association for Cancer Research -Japanese Cancer Association Joint International Conference (2007 AACR-JCA Conference, Waikoloa, Hawaii, USA)
- 28. Drug-ability Case Study: Exploration of Structural Modifications and their Impact on Oral Bioavailability of Novel Radio-sensitization Agents (Z-(±)-2-(1-Benzylindole-3-yl-methylene)azabicyclo[2.2.2]octane-3-ol and Z-(±)-2-(1-Benzylindole-3-yl-methylene)azabicyclo[2.2.2]octane-3-ol). Al-Ghananeem AM*, Al-Bayati Z, Malkawi A, Sonar VN, Freeman ML and Crooks PA. (2007 233rd ACS National Meeting, Chicago, IL, USA)
- **29.** Nasal Delivery of Δ⁹-Tetrahydrocannabenol Loaded Bioadhesive Chitosan Gels in Rabbits.

 <u>Al-Ghananeem AM</u>*, Malkawi AH and Crooks PA. (2006 AAPS Annual Meeting and Exposition, San Antonio, TX, USA)

- **30.** Scopolamine Sublingual Spray: An Alternative Route of Delivery for the Treatment of Motion Sickness. Al-Ghananeem AM, Malkawi AH and Crooks PA. (2006 AAPS Annual Meeting and Exposition, San Antonio, TX, USA)
- 31. A Highly Sensitive Analytical Method for 5-Fluorouracil in Plasma and Vitreous Humor by Liquid Chromatography-Mass Spectrometry. Malkawi AH, <u>Al-Ghananeem AM</u> and Crooks PA. (2006 AAPS Annual Meeting and Exposition, San Antonio, TX, USA)
- **32. Sublingual Drug Delivery of Oxycodone for Acute Pain Management.** Al-Ghananeem AM*, Malkawi AH and Crooks PA. (2005 AAPS Annual Meeting and Exposition, Nashville, TN, USA)
- **33. Sublingual Drug Delivery of Nicotine for Smoking Cessation.** Al-Ghananeem AM*, Malkawi AH, Wei X and Crooks PA. (2005 AAPS Annual Meeting and Exposition, Nashville, TN, USA)
- **34.** A Gas Chromatography and Mass Selective Method for the Determination of Fentanyl in Plasma at Nanogram Levels. Malkawi AH, <u>Al-Ghananeem AM</u> and Crooks PA. (2004 AAPS Annual Meeting and Exposition, Baltimore, MD, USA)
- **35. A Stability Study of Dantrolene Sodium.** <u>Al-Ghananeem AM</u>*, Neelakantan S and Crooks PA. (2003 AAPS Annual Meeting and Exposition, Salt Lake city, UT, USA)
- 36. Enhancement of Direct Brain Delivery of 17-β Estradiol by the Administration of its Water Soluble Prodrugs via the Nasal Route. Al-Ghananeem AM*, Hussain M, Traboulsi A, Dittert L and Hussain A. (1999 AAPS Annual Meeting and Exposition, New Orleans, LA, USA)
- **37.** Enzymatic Hydrolysis of *O*-2-Acetoxybenzyl-salicylamide. A Potent Oral Analgesic. Wang H, Hussain A, <u>Al-Ghananeem AM</u> and Wedlund P. (1999 AAPS Annual Meeting and Exposition, New Orleans, LA, USA)